Chimerix Inc.

(CMRX) Trade

By |

Profile

Chimerix Inc is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV). The DSTAT is a glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy. The BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox.

Contact Information

Website: www.chimerix.com
Email: ir@chimerix.com
Main Phone: +1 919 806-1074
Address: 2505 Meridian Parkway
Address 2: Suite 100
State: NC
City / Town: Durham
Country: USA
Postal Code: 27713

Issuer Information

Exchange: NSD
CEO: Michael Sherman
Employees: 43
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Chimerix Inc is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV). The DSTAT is a glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy. The BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox.

Contact Information

Website: www.chimerix.com
Email: ir@chimerix.com
Main Phone: +1 919 806-1074
Address: 2505 Meridian Parkway
Address 2: Suite 100
State: NC
City / Town: Durham
Country: USA
Postal Code: 27713

Issuer Information

Exchange: NSD
CEO: Michael Sherman
Employees: 43
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 1.49 $ -0.02 (-1.32%)
Last Price 1.49 Change $ -0.02 Change % -1.32 Tick N/A
Bid 1.44 Bid Size 200.00 Ask 1.48 Ask Size 100.00
Open 1.47 High 1.53 Low 1.37 Prev Close 1.51
Last Trade Volume 266,630 52 Wk Hi 4.41 52 Wk Low 1.20
Market Cap 92 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 61,740,646.00 EPS (TTM) -1.95 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 12 17
Number of Buys 2 4
Number of Sells 10 13
Net Activity -155118 -146026
Last 10 Buys Shares
M. Michelle Berrey 1,000
M. Michelle Berrey 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Timothy W. Trost 1,000
Ernest Mario 1,000
Last 10 Sell Shares
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Ernest Mario 1,000
Linda M. Richardson 1,000
Ernest Mario 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 10 10 10 10
Low Target Price Estimate 4 4 4 4
Mean Target Price Estimate 6.75 6.75 6.75 6.75
Standard Deviation 2.5 2.5 2.5 2.5
Date of Most Recent Estimate 05/08/18 05/08/18 05/08/18 05/08/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 3.22 3.22 3.22 3.22